H. Manning
Faculty Member
Last active: 3/22/2018

  1. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, Sharick JT, Skala MC, Smith JA, Berlin J, Washington MK, Nickels ML, Manning HC (2018) Nat Med 24(2): 194-202
    › Primary publication · 29334372 (PubMed) · PMC5803339 (PubMed Central)
  2. Intracardiac Metastases Detected by 18F-FSPG PET/CT. Magarik MA, Walker RC, Gilbert J, Manning HC, Massion PP (2018) Clin Nucl Med 43(1): 28-30
    › Primary publication · 29076915 (PubMed) · PMC5716866 (PubMed Central)
  3. Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation. Tang D, Fujinaga M, Hatori A, Zhang Y, Yamasaki T, Xie L, Mori W, Kumata K, Liu J, Manning HC, Huang G, Zhang MR (2018) Eur J Med Chem : 1-8
    › Primary publication · 29505933 (PubMed)
  4. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM (2018) Nat Commun 9(1): 248
    › Primary publication · 29339738 (PubMed) · PMC5770411 (PubMed Central)
  5. Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening. Li J, Smith JA, Dawson ES, Fu A, Nickels ML, Schulte ML, Manning HC (2017) Bioconjug Chem 28(4): 1016-1023
    › Primary publication · 28156095 (PubMed)
  6. Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF In Vivo. Schulte ML, Hight MR, Ayers GD, Liu Q, Shyr Y, Washington MK, Manning HC (2017) Mol Imaging Biol 19(3): 421-428
    › Primary publication · 27770401 (PubMed) · PMC6476310 (PubMed Central)
  7. F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA (2017) Clin Cancer Res 23(12): 3053-3060
    › Primary publication · 28011460 (PubMed) · PMC5474190 (PubMed Central)
  8. Evaluation of TSPO PET Ligands [F]VUIIS1009A and [F]VUIIS1009B: Tracers for Cancer Imaging. Tang D, Li J, Buck JR, Tantawy MN, Xia Y, Harp JM, Nickels ML, Meiler J, Manning HC (2017) Mol Imaging Biol 19(4): 578-588
    › Primary publication · 27853987 (PubMed) · PMC5634614 (PubMed Central)
  9. A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI. Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC (2017) Magn Reson Imaging : 195-202
    › Primary publication · 27919785 (PubMed) · PMC5316364 (PubMed Central)
  10. Utility of [F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population. Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC (2016) Mol Imaging Biol 18(6): 924-934
    › Primary publication · 27677886 (PubMed) · PMC5641676 (PubMed Central)